131 related articles for article (PubMed ID: 27174013)
1. High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging.
Lou S; Balluff B; de Graaff MA; Cleven AH; Briaire-de Bruijn I; Bovée JV; McDonnell LA
Proteomics; 2016 Jun; 16(11-12):1802-13. PubMed ID: 27174013
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.
Lou S; Balluff B; Cleven AHG; Bovée JVMG; McDonnell LA
J Am Soc Mass Spectrom; 2017 Feb; 28(2):376-383. PubMed ID: 27873216
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.
Villacis RA; Silveira SM; Barros-Filho MC; Marchi FA; Domingues MA; Scapulatempo-Neto C; Aguiar S; Lopes A; Cunha IW; Rogatto SR
PLoS One; 2014; 9(7):e102281. PubMed ID: 25028927
[TBL] [Abstract][Full Text] [Related]
4. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
5. Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis.
Guled M; Pazzaglia L; Borze I; Mosakhani N; Novello C; Benassi MS; Knuutila S
Genes Chromosomes Cancer; 2014 Aug; 53(8):693-702. PubMed ID: 24771630
[TBL] [Abstract][Full Text] [Related]
6. Multicenter matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) identifies proteomic differences in breast-cancer-associated stroma.
Dekker TJ; Balluff BD; Jones EA; Schöne CD; Schmitt M; Aubele M; Kroep JR; Smit VT; Tollenaar RA; Mesker WE; Walch A; McDonnell LA
J Proteome Res; 2014 Nov; 13(11):4730-8. PubMed ID: 24762205
[TBL] [Abstract][Full Text] [Related]
7. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity.
Willems SM; van Remoortere A; van Zeijl R; Deelder AM; McDonnell LA; Hogendoorn PC
J Pathol; 2010 Dec; 222(4):400-9. PubMed ID: 20839361
[TBL] [Abstract][Full Text] [Related]
8. The radiology of sarcomas and sarcomatoid carcinomas of the kidney.
Mucci B; Lewi HJ; Fleming S
Clin Radiol; 1987 May; 38(3):249-54. PubMed ID: 3555960
[TBL] [Abstract][Full Text] [Related]
9. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma.
Piano MA; Brunello A; Cappellesso R; Del Bianco P; Mattiolo A; Fritegotto C; Montini B; Zamuner C; Del Fiore P; Rastrelli M; Sommariva A; De Salvo GL; Montesco MC; Rossi CR; Zagonel V; Calabrò ML
Clin Cancer Res; 2020 Jun; 26(12):2921-2931. PubMed ID: 32127392
[TBL] [Abstract][Full Text] [Related]
10. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling.
Kikuta K; Kubota D; Yoshida A; Qiao Z; Morioka H; Nakamura M; Matsumoto M; Chuman H; Kawai A; Kondo T
Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1160-1166. PubMed ID: 28668639
[TBL] [Abstract][Full Text] [Related]
11. MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays.
Steurer S; Singer JM; Rink M; Chun F; Dahlem R; Simon R; Burandt E; Stahl P; Terracciano L; Schlomm T; Wagner W; Höppner W; Omidi M; Kraus O; Kwiatkowski M; Doh O; Fisch M; Soave A; Sauter G; Wurlitzer M; Schlüter H; Minner S
Urol Oncol; 2014 Nov; 32(8):1225-33. PubMed ID: 25131659
[TBL] [Abstract][Full Text] [Related]
12. An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging.
Lou S; Balluff B; Cleven AHG; Bovée JVMG; McDonnell LA
Biochim Biophys Acta Proteins Proteom; 2017 Jul; 1865(7):957-966. PubMed ID: 27725306
[TBL] [Abstract][Full Text] [Related]
13. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma.
Elsner M; Rauser S; Maier S; Schöne C; Balluff B; Meding S; Jung G; Nipp M; Sarioglu H; Maccarrone G; Aichler M; Feuchtinger A; Langer R; Jütting U; Feith M; Küster B; Ueffing M; Zitzelsberger H; Höfler H; Walch A
J Proteomics; 2012 Aug; 75(15):4693-704. PubMed ID: 22365974
[TBL] [Abstract][Full Text] [Related]
14. miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
Pazzaglia L; Novello C; Conti A; Pollino S; Picci P; Benassi MS
Cell Oncol (Dordr); 2017 Feb; 40(1):77-88. PubMed ID: 27900663
[TBL] [Abstract][Full Text] [Related]
15. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.
Lemaire R; Menguellet SA; Stauber J; Marchaudon V; Lucot JP; Collinet P; Farine MO; Vinatier D; Day R; Ducoroy P; Salzet M; Fournier I
J Proteome Res; 2007 Nov; 6(11):4127-34. PubMed ID: 17939699
[TBL] [Abstract][Full Text] [Related]
16. Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas.
Silveira SM; Villacis RA; Marchi FA; Barros Filho Mde C; Drigo SA; Neto CS; Lopes A; da Cunha IW; Rogatto SR
PLoS One; 2013; 8(6):e67643. PubMed ID: 23825676
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types.
Murray E; Hernychová L; Scigelova M; Ho J; Nekulova M; O'Neill JR; Nenutil R; Vesely K; Dundas SR; Dhaliwal C; Henderson H; Hayward RL; Salter DM; Vojtěšek B; Hupp TR
J Proteome Res; 2014 May; 13(5):2543-59. PubMed ID: 24661138
[TBL] [Abstract][Full Text] [Related]
19. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
20. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?
Carneiro A; Francis P; Bendahl PO; Fernebro J; Akerman M; Fletcher C; Rydholm A; Borg A; Nilbert M
Lab Invest; 2009 Jun; 89(6):668-75. PubMed ID: 19290004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
